IngredientsFerric orthophosphate — formally ferric phosphate, iron(III) phosphate, FePO₄·xH₂O, CAS Registry No. 10045-86-0 — is an odorless, yellowish-white to buff-colored powder that contains from one to four molecules of water of hydration. It is an inorganic phosphate salt in which iron is held in its +3 oxidation state (ferric) and is bound to phosphate ions. It is prepared by reaction of sodium phosphate with ferric chloride or ferric citrate.
The compound carries numerous synonyms in the scientific and regulatory literature. These include Ferramol, Ferrum Phosphoricum, and Iron(3+) Phosphate. In homeopathic preparations, the compound is commonly designated Ferrum Phosphoricum. The anhydrous form carries CAS No. 10402-24-1, while the hydrated nutritional form is identified by CAS No. 10045-86-0.
Ferric orthophosphate is the inorganic compound with the formula FePO₄. Ferric orthophosphate is insoluble in water but is readily soluble in dilute mineral acids. This combination of properties — stable, unreactive, and effectively non-soluble at neutral pH — is central to understanding both its utility in food fortification and its variable bioavailability as a nutritional source.
Ferric orthophosphate (FePO₄) is preferred over elemental iron for liquid products, light-colored food, and oxidatively sensitive food applications because of its low density, light color, good stability, and non-metallic flavor. Soluble iron such as ferrous sulfate is a pro-oxidant, has a metallic off-taste, and reacts with many food components causing negative organoleptic changes and shortened shelf life, making ferric orthophosphate an attractive alternative for certain applications.
Commercial preparations used in food fortification are described as food-grade powders. By supplier specification, all FePO₄ sources used in fortification studies were food grade and >99% pure, with pH ranging from 3 to 5. Semi-crystalline materials such as FePO₄ have varying degrees of molecular disorder, referred to as amorphous content, which is hypothesized to be an important factor in bioavailability. The iron content of the dry compound is approximately 29% by weight.
Ferric orthophosphate, also known as iron(III) phosphate, has been utilized for decades as a nutritional iron supplement, particularly in the fortification of cereal products, infant formulas, and other foods. Its use as a supplement dates to the early 20th century when efforts to combat iron deficiency anemia led to the exploration of various iron salts for food fortification.
Ferric orthophosphate emerged in the late 19th and early 20th centuries as a preferred iron supplement, valued for its relatively gentle effect on the digestive system compared to other iron salts. It emerged as a preferred option due to its stability, low reactivity with food ingredients, and minimal impact on taste and color.
In homeopathic traditions, the compound is prescribed under the name Ferrum Phosphoricum and has been used in the Schuessler tissue salt system since the late 1800s. However, no peer-reviewed clinical evidence supports the efficacy of homeopathic preparations of ferric orthophosphate for any condition, and such preparations contain negligible elemental iron by modern analytical standards.
In Europe, the relatively nonreactive and insoluble ferric orthophosphate and ferric pyrophosphate have been widely used to fortify infant cereals and related products. The use of ferric orthophosphate in flour and cereal fortification programs became formalized from the mid-20th century onward, paralleling the broader development of systematic food enrichment policy. According to a Mintel Global New Product Database search from January 1996 to January 2016, there were 2,121 food and beverage products including snack/cereal/energy bars, hot and cold cereals, enriched rice, and meal replacement drinks containing FePO₄ marketed globally.
Ferric orthophosphate supplies two essential minerals in a single compound: iron (approximately 29% by elemental weight) and phosphorus (as orthophosphate). As an iron source in the diet, its nutritional significance is primarily as a provider of non-heme iron. The phosphate component, while present, contributes only modestly to total dietary phosphorus intake at the amounts used in food fortification.
Ferrous iron from fortificants and foods is absorbed in the duodenum via the divalent metal transporter 1 (DMT1). Ferric iron must be reduced to the ferrous state before uptake by DMT1. Because ferric orthophosphate is a ferric (Fe³⁺) compound, it must undergo dissolution in the acid environment of the stomach and subsequent reduction before it can be absorbed.
To be absorbed by the small intestine, some portion of the dietary iron must first dissolve in stomach acid. Ferric iron, which is insoluble at physiological pH, is released from the food matrix in the acidic environment of the stomach and is chelated by mucins on the duodenal brush border surface, which maintain the iron in the ferric state. In the cytosol, this complex combines with flavin monooxygenase and β2-microglobulin to form a larger conglomerate known as paraferritin, which has ferric reductase activity resulting in the conversion of the absorbed Fe³⁺ to Fe²⁺.
Much of the dietary iron in the intestinal lumen is in the oxidized or ferric (Fe³⁺) form, yet it is ferrous iron (Fe²⁺) that is more soluble and is the substrate for the major brush border membrane iron transporter DMT1. Ferric iron must thus first be reduced before it can be utilized. One identified candidate ferrireductase is the transmembrane protein DCYTB, which has iron reductase activity in vitro, and an antibody against DCYTB inhibits iron reduction in duodenal samples.
Since iron cannot be actively excreted in mammals and iron overload is toxic, iron absorption through DMT1 is tightly regulated by iron stores and circulating hepcidin. This regulatory mechanism applies to iron derived from ferric orthophosphate in the same manner as to other non-heme iron sources once the ferrous form has been generated.
Compared to highly soluble iron salts such as ferrous sulfate, standard ferric orthophosphate has lower bioavailability. This reduced effectiveness is directly related to its high insolubility. The solubilities of the various elemental or compound forms of iron depend on their method of manufacture which, in turn, may result in a wide range of bioavailabilities even for the same form of iron.
The dissolution and absorption of poorly-soluble iron compounds is inversely related to particle size, and nanostructured iron compounds may be useful as food fortificants or supplements. Reducing particle size to the nanoscale dramatically increases surface area relative to volume, which increases the proportion of iron released under gastric acid conditions — the rate-limiting step in ferric orthophosphate absorption.
Under U.S. federal regulations (21 CFR §184.1301), ferric phosphate (ferric orthophosphate, iron (III) phosphate, FePO₄·xH₂O, CAS Reg. No. 10045-86-0) is described as an odorless, yellowish-white to buff-colored powder containing from one to four molecules of water of hydration, prepared by reaction of sodium phosphate with ferric chloride or ferric citrate. In accordance with §184.1(b)(1), the ingredient is used in food as a nutrient supplement as defined in §170.3(o)(20) of the code, with no limitation other than current good manufacturing practice. This places it firmly within the category of substances Generally Recognized as Safe (GRAS) under the FDA framework.
Ferric orthophosphate is not allowed as a food additive in the European Union; it was withdrawn from the list of allowed substances. This position distinguishes the EU regulatory landscape from that of the United States and other jurisdictions. EFSA's decisions about permitted iron sources for food fortification and supplements are governed by Directive 2002/46/EC and subsequent regulations; ferric orthophosphate did not remain on the permitted list following safety re-evaluations, though other ferric and ferrous compounds are permitted.
Within the category of iron fortificants evaluated by WHO/FAO, the ferric phosphate compounds — ferric orthophosphate and ferric pyrophosphate — are used to fortify rice, and some infant cereals and chocolate-containing foods. They have modest iron availability: the relative bioavailability of ferric pyrophosphate is reported to be 21–74%, and that of ferric orthophosphate, 25–32%.
Iron deficiency anemia (IDA) is a major global public health problem. IDA particularly affects women of childbearing age, and iron fortification of foods is a recommended strategy to prevent it. Ferric orthophosphate has been investigated both as a direct supplement and as a food fortification agent for the correction and prevention of IDA.
The unexpectedly low bioavailability in humans of elemental iron powder prompted researchers to search for other iron compounds suitable for flour fortification that fulfill the two requirements of insolubility in water and good bioavailability in humans. Systematic studies of compatibility, solubility, and bioavailability led to investigation of a microcrystalline complex ferric orthophosphate (CFOP), Fe₃H₈(NH₄)(PO₄)₆·6H₂O.
A human isotope study published in the American Journal of Clinical Nutrition (Hallberg, Rossander-Hultén, Gramatkovski, 1989) measured iron absorption from CFOP using dual radioisotope labeling. The compound was labeled with ⁵⁹Fe, and native iron in meals was labeled with ⁵⁵FeCl₃. The ratio of absorbed ⁵⁹Fe to absorbed ⁵⁵Fe provided a direct measure of the fraction of CFOP joining the nonheme iron pool. The relative bioavailability of CFOP varied from 30% to 60% when labeled wheat rolls were served with different meals. The variability across meals underscored the importance of the dietary matrix in determining how much ferric orthophosphate is ultimately absorbed.
Clinical studies have demonstrated the ability of ferric orthophosphate to increase hemoglobin and ferritin levels, particularly when used in population-level interventions to address iron deficiency. However, the strength of this evidence varies considerably depending on the formulation, particle size, and food vehicle used. The WHO acknowledges ferric orthophosphate as a permitted iron fortification compound but notes its relatively low relative bioavailability (RBV) compared to ferrous sulfate.
The standard reference for assessing iron bioavailability is ferrous sulfate (FeSO₄), which is assigned an RBV of 100%. Multiple studies have measured ferric orthophosphate against this benchmark.
In a study at the University level assessing five commercial FePO₄ sources and ferrous sulfate added to individual batches of ready-to-eat (RTE) cereal, the relative bioavailability value (RBV) of each iron source, determined using the AOAC Rat Hemoglobin Repletion Bioassay, ranged from 51% to 99%. This wide range across commercial suppliers emphasizes that manufacturer-specific physicochemical properties — not just the chemical identity of ferric orthophosphate — substantially determine nutritional value.
The WHO guidelines on food fortification report a narrower range specifically for human data: the relative bioavailability of ferric orthophosphate is reported to be 25–32%; however, the relative availability of the ferric phosphates may change during the processing of a food.
Poorly acid-soluble iron compounds such as ferric phosphate (FePO₄) in bulk form are stable in foods, but their absorption in humans is too low to have nutritional value. This is a particularly important regulatory and public health consideration: while ferric orthophosphate improves the analytical iron content on a nutrition label, the fraction bioavailable to consumers may be insufficient to meaningfully address deficiency unless the food vehicle, processing conditions, and co-ingested nutrients are optimized.
A significant body of emerging research has focused on overcoming the bioavailability limitations of bulk ferric orthophosphate through nanotechnology. Rodent studies show that nano-sized ferric phosphate (NP-FePO₄) is as bioavailable as ferrous sulfate.
In an anemic rat model, iron bioavailability from two FePO₄-NP compounds was 75% and 95%, respectively, compared to the ionic reference compound FeSO₄. However, animal-to-human translation is uncertain: rodents absorb iron efficiently because they endogenously synthesize ascorbic acid, have lower duodenal pH, and are less affected by dietary absorption inhibitors than humans. Thus, whether the high bioavailability of FePO₄-NP determined in rats can be extrapolated to humans is unknown, since existing animal models were never validated with nano compounds.
A key human clinical study (published in Scientific Reports, 2022) assessed nanostructured FePO₄ in iron deficient anemic women using a randomized, cross-over design with stable-isotope labeling. Absorption and subsequent erythrocyte iron utilization from two ⁵⁷Fe-labeled FePO₄-NP with specific surface areas of 98 m²/g and 188 m²/g was 2.8-fold and 5.4-fold higher than from bulk FePO₄ with a specific surface area of 25 m²/g (P < 0.001) when added to a rice and vegetable meal. The FePO₄-NP with SSA 188 m²/g achieved 72% relative bioavailability compared to FeSO₄. These data suggest FePO₄-NPs may be useful for nutritional applications.
Absorption of iron from FePO₄-NP appears to be largely DMT1-dependent, and its biodistribution after absorption is similar to that from FeSO₄, without abnormal deposition of iron in the reticuloendothelial system. Whether iron from FePO₄-NP can be absorbed independently of the DMT1 pathway in vivo remains uncertain.
Evidence strength summary for nanostructured forms: Preliminary to moderate. Rodent data are strong and consistent; the pivotal human cross-over study (2022) is promising but limited to a single setting, one food matrix (rice and vegetable meal), and iron deficient anemic women. Long-term safety and efficacy data from randomized controlled trials in diverse populations are not yet available.
Ferric orthophosphate has had limited use as an iron fortificant in ready-to-eat (RTE) cereal because of its variable bioavailability, the mechanism of which is poorly understood. Even though FePO₄ has desirable sensory properties compared to other affordable iron fortificants, few published studies have well characterized its physicochemical properties.
Semi-crystalline materials such as FePO₄ have varying degrees of molecular disorder, referred to as amorphous content, which is hypothesized to be an important factor in bioavailability. Research at major nutrition institutes has investigated how particle size, surface area, amorphous content, and acid solubility interact to predict absorption, seeking to identify which commercial FePO₄ grades are nutritionally meaningful. The rat hemoglobin repletion bioassay RBVs ranging from 51–99% across five commercial sources demonstrate that the nutritional quality of commercially available ferric orthophosphate cannot be assumed uniform.
Ferric orthophosphate has been utilized for decades as a nutritional iron supplement, particularly in the fortification of cereal products and infant formulas. In Europe, the relatively nonreactive and insoluble ferric orthophosphate and ferric pyrophosphate are also widely used to fortify infant cereals.
Infant cereals are commonly fortified with insoluble iron compounds with low relative bioavailability, such as ferric pyrophosphate, because of organoleptic changes that occur after addition of water-soluble iron sources. Ferric orthophosphate fills the same functional niche: it does not discolor or impart a metallic taste to white or beige-colored infant cereals. However, the same low bioavailability concern applies to both ferric compounds in infants.
Evidence strength summary for infant fortification: Moderate for the proposition that ferric orthophosphate increases analytical iron content and can improve iron status at a population level; weak to moderate for the proposition that it is as efficacious as ferrous sulfate or ferrous fumarate in correcting established IDA in infants, given its documented lower RBV in human studies.
Iron is required for normal neurodevelopment and cognitive function, particularly in infants and young children. Iron deficiency during critical developmental windows is associated with impaired cognitive outcomes. Although iron supplementation and fortification have been studied in relation to cognitive outcomes, no clinical studies identified in authoritative databases have specifically attributed cognitive benefits to ferric orthophosphate as a distinct compound, separate from the general class of non-heme iron fortification. The cognitive effects observed in iron intervention studies are understood to stem from correction of iron deficiency per se (and its downstream effects on hemoglobin, myelin synthesis, and dopaminergic neurotransmission) rather than from properties unique to ferric orthophosphate.
Ferric orthophosphate is used primarily as a food fortification ingredient rather than as a standalone supplement in capsule or tablet form. Dosage data in the literature reflect fortification levels in food vehicles rather than therapeutic supplementation regimens.
The risk of iron overload from dietary sources of iron is low among adults who have normal intestinal function, but high doses of iron supplements can cause a range of gastrointestinal effects. With extremely high doses, these effects can be severe, including corrosive necrosis of the intestine, multisystem organ failure, and even death. The Tolerable Upper Intake Level for iron is 45 mg for adults, and it ranges from 40 mg to 45 mg for infants, children, and adolescents, depending on age. These values apply to total iron intake from all sources, including ferric orthophosphate.
EFSA's 2024 systematic review of the tolerable upper intake level for iron concluded that it is established that systemic iron overload leads to organ toxicity, but no formal UL could be established. The only indicator for which a dose–response could be established was black stools, which reflect the presence of large amounts of unabsorbed iron in the gut. EFSA set a safe level of total iron intake at 40 mg/day for adults, including pregnant and lactating women; a range of values for minors, from 10 mg/day (children aged 1–3) to 35 mg/day (adolescents aged 15–17); and 5 mg/day for infants aged 4–11 months, covering iron intakes from fortified food and food supplements.
Fe(III) (ferric) ions are often used in maltol or polymaltose complexes to avoid toxicity. Fe(III) is particularly beneficial for patients with iron deficiency anemia who need long-term supplementation, reflecting a clinical preference for ferric forms in some therapeutic settings due to their lower likelihood of gastrointestinal irritation at therapeutic doses. Because ferric orthophosphate is poorly soluble at gastrointestinal pH and releases iron slowly, it is generally associated with fewer acute gastrointestinal adverse effects than highly soluble ferrous salts, though this characteristic simultaneously contributes to its lower bioavailability.
Because ferric orthophosphate is a non-heme iron compound, its absorption is subject to the same dietary modulators that affect all non-heme iron:
Ferric phosphate itself is generally considered safe and does not pose a significant risk of iron toxicity when consumed within recommended limits. However, excessive intake of iron, whether from ferric phosphate or other sources, can lead to iron overload and potential toxicity. Individuals with hereditary hemochromatosis, thalassemia major, sideroblastic anemia, or other iron-loading disorders are at elevated risk for iron accumulation, and the addition of any iron-containing compound — including ferric orthophosphate — to the diet requires careful clinical management in these populations.
Continuous oral iron supplementation with ferrous (Fe(II)) compounds may disturb copper-zinc homeostasis. Ferric compounds such as ferric orthophosphate, being less readily absorbed, theoretically carry a lower risk of this interaction at fortification doses, but this has not been rigorously studied for ferric orthophosphate specifically.
Non-heme iron, the form supplied by ferric orthophosphate, is known to interact with a range of pharmaceuticals through several mechanisms:
Iron phosphate is one of the few molluscicides approved for use in organic farming. Pesticide pellets containing iron phosphate plus a chelating agent such as EDTA leach heavy metals from soil into groundwater. The Research Institute of Organic Agriculture (FiBL) reported the EDTA content and stated such products were likely to be no safer than metaldehyde baits. This concern pertains specifically to agricultural formulations and is not applicable to food-grade or supplement-grade ferric orthophosphate, which does not contain EDTA.
The scientific literature on ferric orthophosphate as a nutritional ingredient is characterized by several consistent findings: it is a chemically well-defined, physically stable compound that is safe at fortification doses; its principal limitation is variable and often low bioavailability attributable to its insolubility at non-acidic pH; its RBV in humans, relative to ferrous sulfate, is consistently reported in the range of 25–60% depending on formulation, particle size, and food matrix; and its bioavailability can be significantly improved by co-administration with ascorbic acid and is significantly diminished in the presence of phytates and polyphenols. Research on nanostructured ferric phosphate is promising but remains preliminary in humans. No evidence from high-quality randomized controlled trials demonstrates that ferric orthophosphate is superior to ferrous sulfate or ferrous fumarate for correcting iron deficiency anemia in any population.
Health conditions that Ferric orthophosphate may help support.
Body systems that Ferric orthophosphate may help support.
Go back